KCNA3 and epilepsy: The clinical usefulness of this potassium channel blocker may be hampered by its proconvulsant activity and cardiac safety issues at higher doses, thus the benefit/risk profile of 4-AP in KCNA2 epilepsy should be carefully investigated and eventually new derivatives developed [14,44].